<DOC>
	<DOCNO>NCT02919995</DOCNO>
	<brief_summary>This study evaluate two dos RPL554 placebo adult patient cystic fibrosis . All patient receive three treatment randomise sequence .</brief_summary>
	<brief_title>A Study RPL554 Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Sign inform consent document indicate understand purpose procedure require study willing participate study . 2 . Male female age ≥18 year time inform consent . Females childbearing potential must use consistent reliable form contraception ( see Appendix 1 ) last menses first study treatment administration , must commit continue study 3 month last dose study treatment . 3 . Have 12lead ECG record screening ( Visit 1 ) Visit 2 predose show following : Heart rate 45 90 beat per minute QT interval correct heart rate use Fridericia 's formula ( QTcF ) interval ≤450 msec QRS interval ≤120 msec PR interval ≤220 msec No clinically significant abnormality include morphology ( e.g . leave bundle branch block , atrioventricular nodal dysfunction , ST segment abnormality ) 4 . Capable comply study restriction procedure include ability use study nebuliser correctly . 5 . Body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) minimum weight 40 kg . 6 . Patients genetic diagnosis CF . 7 . Spirometry screen demonstrate FEV1 ≥40 % ≤80 % predict normal . 8 . Capable withdraw long act bronchodilators1 end treatment period , short act bronchodilator 8 hour prior administration study treatment . 9 . Clinically stable CF 2 week prior randomisation ( Visit 2 ) . 1 . History cirrhotic liver disease portal hypertension . 2 . CF exacerbation require hospitalisation month prior screen ( Visit 1 ) prior randomisation ( Visit 2 ) . 3 . Use oral intravenous antibiotic ( additional usual maintenance therapy ) 2 week prior screen ( Visit 1 ) randomisation ( Visit 2 ) . 4 . Other nonCF related respiratory disorder : Patients current diagnosis active tuberculosis , lung cancer , sarcoidosis , sleep apnoea , know alpha1 antitrypsin deficiency active pulmonary disease . 5 . Previous lung resection lung transplant . 6 . History , reason believe patient , drug alcohol abuse within past 3 year . 7 . Received experimental drug within 3 month five halflives , whichever longer . 8 . Patients history chronic uncontrolled disease include , limited , cardiovascular ( include arrhythmia ) , endocrine , active hyperthyroidism , neurological , hepatic , gastrointestinal , renal , haematological , urological , immunological ophthalmic disease Investigator believe clinically significant . 9 . Documented cardiovascular disease : angina , recent suspect myocardial infarction , congestive heart failure , history unstable , uncontrolled hypertension , diagnose hypertension last 3 month . 10 . Has major surgery , ( require general anaesthesia ) 6 week prior screen ( Visit 1 ) fully recover surgery , plan surgery end study . 11 . Infection nontuberculous mycobacteria , methicillinresistant Staphylococcus aureus ( MRSA ) , Burkholderia specie . 12 . Use immunesuppression ; long term use prednisolone ≥10 mg/day . 13 . History malignancy organ system within 5 year exception localise skin cancer ( basal squamous cell ) . 14 . Clinically significant abnormal value safety laboratory test ( haematology , biochemistry urinalysis ) screening ( Visit 1 ) , determine Investigator . 15 . A disclosed history one know Investigator , significant noncompliance previous investigational study prescribe medication . 16 . Requires oxygen therapy , even occasional basis . 17 . Pregnancy lactation ( female subject ) . 18 . Any reason Investigator considers make patient unsuitable participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>